Longwood Capital Partners Has Cut Vanda Pharmaceuticals (VNDA) Holding; Driehaus Capital Management Has Cut Enbridge (ENB) Holding

June 7, 2017 - By Vivian Currie

Driehaus Capital Management Llc decreased Enbridge Inc (ENB) stake by 32.66% reported in 2016Q4 SEC filing. Driehaus Capital Management Llc sold 23,291 shares as Enbridge Inc (ENB)’s stock declined 5.78%. The Driehaus Capital Management Llc holds 48,019 shares with $2.02M value, down from 71,310 last quarter. Enbridge Inc now has $64.62 billion valuation. The stock declined 1.82% or $0.72 reaching $38.86 per share. About 1.06 million shares traded. Enbridge Inc (USA) (NYSE:ENB) has declined 0.40% since June 7, 2016 and is downtrending. It has underperformed by 17.10% the S&P500.

Longwood Capital Partners Llc decreased Vanda Pharmaceuticals Inc (VNDA) stake by 33.9% reported in 2016Q4 SEC filing. Longwood Capital Partners Llc sold 83,395 shares as Vanda Pharmaceuticals Inc (VNDA)’s stock declined 5.00%. The Longwood Capital Partners Llc holds 162,600 shares with $2.59 million value, down from 245,995 last quarter. Vanda Pharmaceuticals Inc now has $614.82M valuation. The stock declined 0.36% or $0.05 reaching $13.75 per share. About 109,380 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since June 7, 2016 and is uptrending. It has outperformed by 34.90% the S&P500.

Among 14 analysts covering Enbridge Inc. (NYSE:ENB), 7 have Buy rating, 0 Sell and 7 Hold. Therefore 50% are positive. Enbridge Inc. had 18 analyst reports since August 4, 2015 according to SRatingsIntel. On Thursday, September 1 the stock rating was initiated by Bank of America with “Neutral”. The rating was initiated by JP Morgan with “Overweight” on Tuesday, December 15. The stock of Enbridge Inc (USA) (NYSE:ENB) has “Outperform” rating given on Tuesday, March 14 by Credit Suisse. The stock of Enbridge Inc (USA) (NYSE:ENB) has “Buy” rating given on Monday, March 7 by Canaccord Genuity. BMO Capital Markets reinitiated the stock with “Outperform” rating in Wednesday, March 2 report. Wells Fargo maintained Enbridge Inc (USA) (NYSE:ENB) on Monday, April 3 with “Market Perform” rating. The firm has “Market Perform” rating given on Monday, May 15 by Wolfe Research. The company was maintained on Tuesday, March 8 by Credit Suisse. The stock of Enbridge Inc (USA) (NYSE:ENB) earned “Neutral” rating by Credit Suisse on Thursday, February 4. RBC Capital Markets maintained Enbridge Inc (USA) (NYSE:ENB) on Friday, October 9 with “Outperform” rating.

Driehaus Capital Management Llc increased American Campus Communities (NYSE:ACC) stake by 32,634 shares to 65,380 valued at $3.25 million in 2016Q4. It also upped Mgm Resorts International (NYSE:MGM) stake by 32,755 shares and now owns 57,155 shares. Gibraltar Industries Inc (NASDAQ:ROCK) was raised too.

Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on July, 26. They expect $-0.20 EPS, down 400.00% or $0.16 from last year’s $-0.04 per share. After $-0.17 actual EPS reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 17.65% negative EPS growth.

Among 7 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 9 analyst reports since September 2, 2015 according to SRatingsIntel. The rating was reinitiated by Jefferies on Thursday, October 6 with “Buy”. The rating was initiated by Brean Capital with “Buy” on Wednesday, October 21. Piper Jaffray maintained it with “Buy” rating and $16 target in Wednesday, September 2 report. The stock has “Buy” rating by Aegis Capital on Wednesday, November 9. JMP Securities maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday, March 9 with “Market Outperform” rating. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Market Outperform” rating by JMP Securities on Friday, August 26.

Longwood Capital Partners Llc increased Iridex Corp (NASDAQ:IRIX) stake by 333,535 shares to 1.55M valued at $21.85 million in 2016Q4. It also upped Oxford Immunotec Global Plc (NASDAQ:OXFD) stake by 63,019 shares and now owns 470,834 shares. Nabriva Therapeutics Ag was raised too.

Since January 3, 2017, it had 0 insider buys, and 4 selling transactions for $952,121 activity. The insider Baroldi Paolo sold 16,300 shares worth $252,776. Shares for $361,242 were sold by Polymeropoulos Mihael Hristos on Tuesday, January 3. $169,013 worth of stock was sold by Kelly James Patrick on Tuesday, January 3. 10,900 shares valued at $169,090 were sold by Gulino Richard L. on Tuesday, January 3.